Skip to main content

Ulterior Motive in Question with Drug Companies’ Charity

Posted in News on 2.16.2017

The Massachusetts U.S. Attorney’s Office is currently leading a nationwide  investigation into drug companies’ charitable contributions toward organizations that provide financial assistance to patients whose health conditions require expensive drugs. These organizations typically c...


MA Program Reduces APMs

Posted in Updates on 1.2.2017

The second wave of Alosa Health’s Massachusetts program to reduce misuse of antipsychotic medications (APMs) in nursing homes came to a close with the 2016 calendar year. While it is too early to evaluate our impact on this group of nursing homes, we are pleased to announce that nursing homes ...


Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy

Posted in Publications on 12.20.2016

JAMA. 2016;316(22)2257-2258 In September 2016, the head of the FDA’s Center for Drug Evaluation and Research approved a new drug (etiplersen) for the treatment of Duchenne muscular dystrophy, despite an advisory committee who voted 7 to 3 finding no evidence that the drug had clinical ef...


Alosa Joins MA Public Health Association

Posted in Updates on 12.12.2016

Alosa Health is now a member of the Massachusetts Public Health Association (MPHA), an organization devoted to preventing illness, disease, and injury in the state of Massachusetts and particularly among those most vulnerable to health disparities. MPHA is also an affiliate of the American Public He...


Congress Says ‘Yes’ to Fast Track FDA Approvals

Posted in News on 12.9.2016

Last week Congress passed legislation addressing questions of healthcare regulation and public health funding. The 21st Century Cures Bill was able to gain easy approval in both the House and Senate because it contains provisions that appeal to both sides of the aisle and to various industry and pub...


Bill to Ease FDA Approval Draws Praise and Rebuke

Posted in News on 12.1.2016

Alosa Health founder Dr. Jerry Avorn was quoted in the Wall Street Journal regarding a healthcare bill scheduled for a vote in the House next week. The bill in question covers a breadth of topics from funding for biomedical research to opioid addiction to the FDA’s regulatory processes.  ...


Healthcare Bill to Fund Research, Overhaul FDA Regs

Posted in News on 11.30.2016

The $6.3 billion bill that has been called “parting gift” to Vice President Joe Biden contains a smorgasbord of healthcare related provisions, including a commitment to additional funding for cancer research through the National Institutes of Health (NIH). Notably, Biden’s son died...


PACE Launches Hypertension Training

Posted in Updates on 11.15.2016

Alosa Health’s newly updated hypertension training module launched recently through the PACE program in Pennsylvania, providing guidance on the latest evidence on hypertension treatment goals and recommendations for therapy. In keeping with our mission to deliver the most up-to-date evidence a...


Alosa Wins PrEP Bid in Shelby County, TN

Posted in Updates on 11.1.2016

This year Alosa Health will kick-off a new program based in Shelby County, TN to support the county health department’s HIV prevention initiatives. The program will focus on educating primary care providers in high-risk areas about the use of PrEP, or pre-exposure prophylaxis, as an ...


The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform

Posted in Publications on 9.6.2016

JAMA. 2016;316(8)858-871 High prescription drug prices are increasingly straining the budgets of patients, payors and healthcare systems in the United States. In this JAMA clinical review, Drs. Avorn, Kesselheim and Sarpartwari describe the origins for high drug prices and recommend policy options ...